Aldevron

Genetic Immunization - Basic or Optimized Strategy

Our core technology, genetic immunization, enables the development of antibodies against any protein target directly from a cDNA. With this strategy, our proprietary immunization vector is introduced into the host organism, the target protein is expressed, and an immune response is generated. To help identify positive antisera and hybridomas, screening without purified antigen is made possible with the use of our proprietary screening vector. As a pioneer in the field, our Antibody Development Team has successfully applied this technology to over 1,500 target proteins with a very high success rate.

Click to enlarge

Inquire for your free target analysis today!

Whether genetic immunization or peptide or protein immunization, we recommend the best technology for your project! In order to assess which strategy will apply for your antigen, please fill out the Aldevron Antibody Services Questionnaire.

Advantages

Advantages

Rapid turnaround
Time and cost efficient
Immunize and screen without purified protein or peptide
Eliminate the risk of protein contamination
Maximized immune response
Difficult targets (e.g., multi-membrane spanning proteins)
Overcome immunodominance
Generate high affinity antibodies
Develop functional modulators
Simple manipulation of target sequence (e.g., site-directed mutagenesis)
Detailed Advantages & Benefits...

Suitable Applications

Suitable Applications

Flow cytometry
ELISA
Diagnostics
Immunoprecipitation
Therapeutic development
Functional studies

Case Study

Case Study

click to enlarge

Genetic immunization allowed generation of mAbs that differentiate two highly conserved tetraspanin molecules (Claudin 6 and Claudin 9).
Study completed in collaboration with INSERM (Strasbourg, France)

Aldevron's broad-range antibody services built on GENOVAC Antibody Technology™
If you have a specific target in mind, please complete our questionnaire for a free analysis.

As of July 1, 2011 GENOVAC has officially changed it's name to Aldevron Freiburg. The core team and technologies will remain intact. Representing the antibody arm of Aldevron, Aldevron Freiburg will continue being a world leader in genetic immunization utilizing GENOVAC Antibody Technology™.

GENOVAC product and services have been migrated to the Aldevron website and are available at aldevron.com/genovac. If you have any questions, please do not hesitate to contact Aldevron.

GENOVAC was first registered as a limited company (GmbH) in December 1999 in Freiburg im Breisgau, South West Germany, by Fritz Grunert, John Thompson and Wolfgang Zimmermann. The three founders were group leaders at the Institute of Immunobiology, University of Freiburg and have a longstanding experience in tumor biology and the development of antibodies against carcinoembryonic antigen (CEA) and related molecules. During this time, they built up contacts to top laboratories working in the field of tumor biology worldwide.

On January 1, 2004 GENOVAC became a part of Aldevron LLC, USA. Both companies have specialized in the area of genetic immunization to develop antibodies. The combined expertise and clientele continue to strengthen Aldevron as a world-leader in antibody technology.

Aldevron Freiburg is based in Freiburg, Germany, which is located in the middle of one of the largest biotechnology centres (BioValley) at a three nation border in the heart of Europe. This region includes Basel, Freiburg and Strasbourg, which apart from a concentration of large pharmaceutical companies (e.g., Novartis and Roche) all have well-known universities and research institutes (e.g., Friedrich Miescher Institute, Basel and Max-Planck Institute of Immunology in Freiburg)

Continue to www.aldevron.com/genovac →

Genetic immunization allowed generation of mAbs that differentiate
two highly conserved tetraspanin molecules (Claudin 6 and Claudin 9).
Study completed in collaboration with INSERM (Strasbourg, France)